Intellipharmaceutics International Inc. (OTCMKTS:IPCIF – Get Rating) (TSE:I) was the recipient of a significant drop in short interest in December. As of December 30th, there was short interest totalling 500 shares, a drop of 96.2% from the December 15th total of 13,200 shares. Based on an average daily volume of 30,800 shares, the days-to-cover ratio is currently 0.0 days.
Intellipharmaceutics International Stock Performance
Shares of OTCMKTS IPCIF remained flat at $0.08 during midday trading on Thursday. The firm has a market capitalization of $2.54 million, a P/E ratio of -0.32 and a beta of 1.51. Intellipharmaceutics International has a one year low of $0.06 and a one year high of $0.16. The company's 50-day moving average is $0.08 and its 200-day moving average is $0.09.
Get
Intellipharmaceutics International alerts:
About Intellipharmaceutics International
(Get Rating)
Intellipharmaceutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.
Featured Articles
- Get a free copy of the StockNews.com research report on Intellipharmaceutics International (IPCIF)
- Mid-Stream Operator Kinder Morgan: A High-Yield Value For 2023
- Why is T-mobile Down Despite Strong Preliminary Q4 Results?
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
Receive News & Ratings for Intellipharmaceutics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International and related companies with MarketBeat.com's FREE daily email newsletter.
智慧製藥國際公司(場外交易代碼：IPCIF-GET評級)(東京證券交易所代碼：I)是12月份空頭股數價格大幅下降的接受者。截至12月30日，空頭股數共有500股，與12月15日的13,200股相比下降了96.2%。以日均成交量30,800股計算，目前天數與回補比率為0.0天。
IntelliPharmPharmtics International股票表現
週四午盤，OTCMKTS IPCIF的股價持平於0.08美元。該公司的市值為254萬美元，本益比為-0.32，貝塔係數為1.51。IntelliPharmPharmtics International的一年低點為0.06美元，一年高位為0.16美元。該公司50日移動均線切入位在0.08美元，200日移動均線切入位在0.09美元。
到達
國際智慧製藥公司警報：
關於英特爾製藥國際公司
(獲取評級)
IntelliPharmPharmtics International Inc.是一家制藥公司，在美國研究、開發和製造新型和仿製藥的控釋和靶向釋放口服固體劑量藥物。該公司在神經學、心血管、胃腸道、糖尿病和疼痛等不同治療領域基於其獲得專利的HyperMatrix技術開發各種藥物輸送系統、候選產品和一系列產品。
專題文章
- 免費獲取StockNews.com關於IntelliPharmPharmtics International(IPCIF)的研究報告
- 中游運營商Kinder Morgan：2023年的高收益價值
- 為什麼T-Mobile在第四季度初步業績強勁的情況下仍然停產？
- 寶潔收益：一場值得冒險的賭博
- 股市下滑，經濟報告為經濟描繪黯淡圖景
- 如新控股股票與沃倫·巴菲特有什麼關係？
獲得IntelliPharmPharmtics International Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對IntelliPharmPharmtics International和相關公司的最新新聞和分析師評級的每日簡要摘要。
